Single-fraction SBRT has strongest curative evidence in peripheral lung and kidney tumors
ESTRO’s review supports selected single-fraction SBRT applications while highlighting major evidence and toxicity gaps in abdominal tumors.
Tag
sbrt
Very late toxicities emerged more than a decade after stage I lung SBRT
Ten-year lung SBRT survivors developed rare airway, chest-wall and pericardial toxicities, while no local failures occurred beyond year 10.
Higher minimum target dose improved local control after repeat spine SBRT
After repeat spine SBRT, 12-month local failure was 6% with Dmin ≥28 Gy EQD2 versus 36% below that level.
Living ESTRO/OligoCare review maps safety signals for SRT with modern systemic therapy
Across 7,694 patients, most SRT–systemic therapy combinations appeared tolerable, but BRAF/MEK inhibitors, T-DM1 and liver SRT showed caution signals.
Monte Carlo grid size materially changed apparent plan quality in liver SBRT
A 3-mm grid cut Monaco calculation time about threefold but altered target, conformity and dose-falloff metrics despite similar gamma QA.
36.25 Gy/5 showed similar five-year control to 40 Gy/5 in prostate SBRT
After propensity matching, five-year PSA recurrence-free survival was 94.5% with 36.25 Gy versus 93.2% with 40 Gy.
Ultracentral lung SBRT produced more grade 3 toxicity than central SBRT
Grade 3 toxicity was 16.7% for ultracentral versus 8.7% for central lung tumors, with no grade ≥4 events in this real-world cohort.
Adding CyberKnife SBRT to lenvatinib and tislelizumab tracked with longer survival in HCC
IPTW-weighted response was 71.1% versus 37.6%, with median survival 23.0 versus 15.6 months after adding SBRT.
Ablative MR-guided RT achieved 95% local control in GEP-NETs
Among 20 mostly metastatic GEP-NET patients, MR-guided ablative RT achieved 95% local control with acute grade 3 toxicity in 10%.
Perirenal hydrogel spacer reduced bowel dose in simulated kidney SBRT
In one cadaveric RCC plan, stable 1-cm perirenal separation reduced large-bowel Dmax from 34.5 to 22.1 Gy.
SBRT timing relative to chemotherapy did not affect survival in stage I SCLC
Stage I SCLC survival was similar whether SBRT preceded chemotherapy or was delivered after chemotherapy had started.
Stereotactic boost after recent radiotherapy achieved 86.5% one-year local control
A phase I study safely escalated five-fraction stereotactic boosts to 30-35 Gy after recent prior radiotherapy, with 86.5% one-year local control.
Dose-escalated prostate SBRT was associated with worse late urinary quality of life
Late urinary worsening occurred in 80% after >40 Gy prostate SBRT versus 68% after ≤40 Gy, while bowel outcomes remained similar.
Single-fraction lung SBRT achieved 100% estimated one-year local control in selected patients
Single-fraction SBRT achieved 100% estimated 12-month local control without grade ≥3 toxicity in a selected 49-patient cohort.
Mechanistic model predicted six-month lymphocyte depletion after lung SBRT
A circulation-based model predicted post-SBRT lymphocyte trajectories and linked a higher predicted lymphocyte nadir with better survival.